Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 1
1989 1
1990 2
1991 1
1992 2
1993 2
1994 2
1997 4
1999 1
2001 1
2005 1
2014 1
2015 5
2016 7
2017 2
2018 1
2019 1
2021 3
2022 3
2023 3
2024 2
2025 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

43 results

Results by year

Filters applied: . Clear all
Page 1
Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial.
Danese S, Vermeire S, D'Haens G, Panés J, Dignass A, Magro F, Nazar M, Le Bars M, Lahaye M, Ni L, Bravata I, Lavie F, Daperno M, Lukáš M, Armuzzi A, Löwenberg M, Gaya DR, Peyrin-Biroulet L; STARDUST study group. Danese S, et al. Lancet Gastroenterol Hepatol. 2022 Apr;7(4):294-306. doi: 10.1016/S2468-1253(21)00474-X. Epub 2022 Feb 1. Lancet Gastroenterol Hepatol. 2022. PMID: 35120656 Clinical Trial.
The evolution of the Galápagos mantle plume.
Soderman CR, Shorttle O, Gazel E, Geist DJ, Matthews S, Williams HM. Soderman CR, et al. Sci Adv. 2023 Mar 10;9(10):eadd5030. doi: 10.1126/sciadv.add5030. Epub 2023 Mar 10. Sci Adv. 2023. PMID: 36897953 Free PMC article.
Ustekinumab treatment in ulcerative colitis: Real-world data from the Swedish inflammatory bowel disease quality register.
Thunberg J, Björkqvist O, Hedin CRH, Forss A, Söderman C, Bergemalm D; SWIBREG Study Group; Olén O, Hjortswang H, Strid H, Ludvigsson JF, Eriksson C, Halfvarson J. Thunberg J, et al. Among authors: soderman c. United European Gastroenterol J. 2022 Sep;10(7):631-639. doi: 10.1002/ueg2.12275. Epub 2022 Jul 14. United European Gastroenterol J. 2022. PMID: 35834389 Free PMC article.
Long-term outcomes of vedolizumab in inflammatory bowel disease: the Swedish prospective multicentre SVEAH extension study.
Visuri I, Eriksson C, Karlqvist S, Lykiardopoulos B, Karlén P, Grip O, Söderman C, Almer S, Hertervig E, Marsal J, Malmgren C, Delin J, Strid H, Sjöberg M, Bergemalm D, Hjortswang H, Halfvarson J. Visuri I, et al. Among authors: soderman c. Therap Adv Gastroenterol. 2023 May 30;16:17562848231174953. doi: 10.1177/17562848231174953. eCollection 2023. Therap Adv Gastroenterol. 2023. PMID: 37274297 Free PMC article.
43 results